Taysha Gene Therapies (TSHA) Stock Forecast, Price Target & Predictions
TSHA Stock Forecast
Taysha Gene Therapies stock forecast is as follows: an average price target of $6.00 (represents a 224.32% upside from TSHA’s last price of $1.85) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
TSHA Price Target
The average price target for Taysha Gene Therapies (TSHA) is $6.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $5.00. This represents a potential 224.32% upside from TSHA's last price of $1.85.
TSHA Analyst Ratings
According to 8 Wall Street analysts, Taysha Gene Therapies's rating consensus is 'Buy'. The analyst rating breakdown for TSHA stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Taysha Gene Therapies Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | Keith Tapper | BMO Capital | $5.00 | $2.31 | 116.45% | 170.27% |
| Jul 01, 2024 | Christopher Raymond | Piper Sandler | $7.00 | $2.24 | 212.50% | 278.38% |
| May 14, 2024 | Eun Yang | Jefferies | $8.00 | $2.40 | 233.33% | 332.43% |
| Apr 09, 2024 | Christopher Raymond | Raymond James | $9.00 | $2.68 | 235.82% | 386.49% |
| Feb 01, 2023 | Jefferies | $1.50 | $1.64 | -8.54% | -18.92% | |
| Oct 19, 2021 | Matthew Harrison | Morgan Stanley | $39.00 | $17.63 | 121.21% | 2008.11% |
| May 19, 2021 | Kristen Kluska | Cantor Fitzgerald | $44.00 | $21.78 | 102.02% | 2278.38% |
The latest Taysha Gene Therapies stock forecast, released on Aug 14, 2024 by Keith Tapper from BMO Capital, set a price target of $5.00, which represents a 116.45% increase from the stock price at the time of the forecast ($2.31), and a 170.27% increase from TSHA last price ($1.85).
Taysha Gene Therapies Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $7.25 |
| Last Closing Price | $1.85 | $1.85 | $1.85 |
| Upside/Downside | -100.00% | -100.00% | 291.89% |
In the current month, the average price target of Taysha Gene Therapies stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Taysha Gene Therapies's last price of $1.85. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Nov 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jul 23, 2024 | Needham | Underperform | Underperform | Hold |
| Jul 23, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jul 01, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 26, 2024 | BMO Capital | Outperform | Initialise | |
| May 28, 2024 | Piper Sandler | Market Outperform | Market Outperform | Hold |
| May 28, 2024 | Needham | Underperform | Underperform | Hold |
| May 14, 2024 | Jefferies | Buy | Upgrade | |
| Apr 30, 2024 | Needham | Underperform | Underperform | Hold |
| Apr 30, 2024 | Piper Sandler | Market Outperform | Market Outperform | Hold |
| Apr 09, 2024 | Piper Sandler | Market Outperform | Market Outperform | Hold |
| Apr 09, 2024 | Piper Sandler | Overweight | Initialise | |
| Feb 02, 2023 | BTIG | Neutral | Downgrade | |
| Feb 01, 2023 | Canaccord Genuity | Buy | Buy | Hold |
| Feb 01, 2023 | Chardan Capital | Buy | Buy | Hold |
| Feb 01, 2023 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Feb 01, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Feb 01, 2023 | Needham | Buy | Buy | Hold |
Taysha Gene Therapies's last stock rating was published by Canaccord Genuity on Nov 15, 2024. The company gave TSHA a "Buy" rating, the same as its previous rate.
Taysha Gene Therapies Financial Forecast
Taysha Gene Therapies Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.75M | $2.40M | $4.71M | $2.50M |
| Avg Forecast | $2.95M | $2.79M | $2.64M | $2.50M | $1.76M | $1.74M | $1.71M | $1.71M | $2.14M | $1.74M | $2.76M | $2.88M | $2.95M | $2.33M | $2.40M | $2.25M | $11.25M |
| High Forecast | $3.37M | $3.19M | $3.01M | $2.85M | $2.01M | $1.99M | $1.95M | $1.95M | $2.37M | $1.74M | $2.76M | $2.88M | $3.36M | $2.33M | $2.73M | $2.57M | $12.83M |
| Low Forecast | $2.53M | $2.39M | $2.26M | $2.14M | $1.51M | $1.49M | $1.46M | $1.46M | $2.02M | $1.74M | $2.76M | $2.88M | $2.52M | $2.33M | $2.05M | $1.92M | $9.62M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.03% | 1.00% | 2.09% | 0.22% |
Taysha Gene Therapies's average Quarter revenue forecast for Dec 23 based on 5 analysts is $2.95M, with a low forecast of $2.52M, and a high forecast of $3.36M. TSHA's average Quarter revenue forecast represents a -37.85% decrease compared to the company's last Quarter revenue of $4.75M (Sep 23).
Taysha Gene Therapies EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-16.25M | $-22.82M | $-15.92M | $-18.51M |
| Avg Forecast | $590.80K | $558.75K | $528.43K | $499.76K | $352.00K | $348.23K | $341.08K | $341.08K | $428.76K | $347.91K | $551.22K | $576.35K | $589.89K | $466.44K | $479.00K | $450.00K | $2.25M |
| High Forecast | $673.92K | $637.36K | $602.77K | $570.07K | $401.52K | $397.22K | $389.07K | $389.07K | $473.90K | $347.95K | $551.23K | $576.37K | $672.88K | $466.47K | $546.39K | $513.31K | $2.57M |
| Low Forecast | $505.44K | $478.02K | $452.08K | $427.55K | $301.14K | $297.91K | $291.80K | $291.80K | $403.94K | $347.86K | $551.21K | $576.32K | $504.66K | $466.42K | $409.79K | $384.98K | $1.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.84% | -47.63% | -35.37% | -8.23% |
undefined analysts predict TSHA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Taysha Gene Therapies's previous annual EBITDA (undefined) of $NaN.
Taysha Gene Therapies Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-117.09M | $-24.60M | $-20.06M | $-58.06M |
| Avg Forecast | $-22.07M | $-22.12M | $-21.21M | $-21.27M | $-25.54M | $-25.97M | $-25.08M | $-24.48M | $-25.02M | $-23.23M | $-42.04M | $-28.73M | $-29.50M | $-46.24M | $-83.31M | $-95.52M | $-106.89M |
| High Forecast | $-17.92M | $-17.97M | $-17.23M | $-17.27M | $-20.74M | $-21.09M | $-20.37M | $-19.88M | $-24.40M | $-18.86M | $-34.14M | $-23.33M | $-23.96M | $-37.55M | $-67.66M | $-77.58M | $-86.81M |
| Low Forecast | $-26.10M | $-26.17M | $-25.09M | $-25.15M | $-30.21M | $-30.72M | $-29.66M | $-28.95M | $-25.65M | $-27.48M | $-49.73M | $-33.98M | $-34.90M | $-54.70M | $-98.55M | $-112.99M | $-126.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.53% | 0.30% | 0.21% | 0.54% |
Taysha Gene Therapies's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TSHA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Taysha Gene Therapies SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.59M | $5.99M | $8.75M | $7.34M |
| Avg Forecast | $11.74M | $11.11M | $10.50M | $9.93M | $7.00M | $6.92M | $6.78M | $6.78M | $8.52M | $6.92M | $10.96M | $11.46M | $11.73M | $9.27M | $9.52M | $8.94M | $44.72M |
| High Forecast | $13.40M | $12.67M | $11.98M | $11.33M | $7.98M | $7.90M | $7.73M | $7.73M | $9.42M | $6.92M | $10.96M | $11.46M | $13.37M | $9.27M | $10.86M | $10.20M | $51.01M |
| Low Forecast | $10.05M | $9.50M | $8.99M | $8.50M | $5.99M | $5.92M | $5.80M | $5.80M | $8.03M | $6.91M | $10.96M | $11.46M | $10.03M | $9.27M | $8.15M | $7.65M | $38.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 0.63% | 0.98% | 0.16% |
Taysha Gene Therapies's average Quarter SG&A projection for Dec 23 is $11.73M, based on 5 Wall Street analysts, with a range of $10.03M to $13.37M. The forecast indicates a 36.51% rise compared to TSHA last annual SG&A of $8.59M (Sep 23).
Taysha Gene Therapies EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.38 | $-0.32 | $-1.03 |
| Avg Forecast | $-0.08 | $-0.08 | $-0.08 | $-0.08 | $-0.10 | $-0.10 | $-0.09 | $-0.09 | $-0.09 | $-0.09 | $-0.16 | $-0.11 | $-0.11 | $-0.17 | $-0.31 | $-0.36 | $-0.40 |
| High Forecast | $-0.07 | $-0.07 | $-0.06 | $-0.06 | $-0.08 | $-0.08 | $-0.08 | $-0.07 | $-0.09 | $-0.07 | $-0.13 | $-0.09 | $-0.09 | $-0.14 | $-0.25 | $-0.29 | $-0.32 |
| Low Forecast | $-0.10 | $-0.10 | $-0.09 | $-0.09 | $-0.11 | $-0.11 | $-0.11 | $-0.11 | $-0.10 | $-0.10 | $-0.19 | $-0.13 | $-0.13 | $-0.20 | $-0.37 | $-0.42 | $-0.47 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | 1.22% | 0.90% | 2.58% |
According to undefined Wall Street analysts, Taysha Gene Therapies's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TSHA previous annual EPS of $NaN (undefined).
Taysha Gene Therapies Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| CABA | Cabaletta Bio | $2.75 | $16.33 | 493.82% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| BMEA | Biomea Fusion | $4.64 | $23.33 | 402.80% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| PRLD | Prelude Therapeutics | $0.89 | $4.00 | 349.44% | Sell |
| GOSS | Gossamer Bio | $0.87 | $3.75 | 331.03% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| TSHA | Taysha Gene Therapies | $2.03 | $6.00 | 195.57% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| ALEC | Alector | $1.89 | $4.00 | 111.64% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| HOOK | HOOKIPA Pharma | $2.13 | $3.00 | 40.85% | Buy |